Development of a hybrid alphavirus-SARS-CoV-2 pseudovirion for rapid quantification of neutralization antibodies and antiviral drugs.
COVID-19
Ha-CoV-2
SARS-CoV-2
SARS-CoV-2 variants
alphavirus
antiviral drug
coronavirus
lentivirus
mRNA vaccine
neutralizing antibody
pseudovirus
Journal
Cell reports methods
ISSN: 2667-2375
Titre abrégé: Cell Rep Methods
Pays: United States
ID NLM: 9918227360606676
Informations de publication
Date de publication:
28 03 2022
28 03 2022
Historique:
received:
06
08
2021
revised:
24
12
2021
accepted:
17
02
2022
pubmed:
2
3
2022
medline:
2
3
2022
entrez:
1
3
2022
Statut:
ppublish
Résumé
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S)-pseudotyped viruses are commonly used for quantifying antiviral drugs and neutralizing antibodies. Here, we describe the development of a hybrid alphavirus-SARS-CoV-2 (Ha-CoV-2) pseudovirion, which is a non-replicating SARS-CoV-2 virus-like particle composed of viral structural proteins (S, M, N, and E) and an RNA genome derived from a fast-expressing alphaviral vector. We validated Ha-CoV-2 for rapid quantification of neutralization antibodies, antiviral drugs, and viral variants. In addition, as a proof of concept, we used Ha-CoV-2 to quantify the neutralizing antibodies from an infected and vaccinated individual and found that the one-dose vaccination with Moderna mRNA-1273 greatly increased the anti-serum titer by approximately 6-fold. The post-vaccination serum can neutralize all nine variants tested. These results demonstrate that Ha-CoV-2 can be used as a robust platform for the rapid quantification of neutralizing antibodies against SARS-CoV-2 and its emerging variants.
Identifiants
pubmed: 35229082
doi: 10.1016/j.crmeth.2022.100181
pii: S2667-2375(22)00036-4
pmc: PMC8866097
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antiviral Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
100181Informations de copyright
© 2022 The Author(s).
Déclaration de conflit d'intérêts
A patent application has been filed by George Mason University and is licensed for product development. Y.W. is a founder of Virongy Biosciences, Inc., and a member of its advisory board. T.C. is the chief scientific officer of Polaris Genomics, Inc.
Références
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Cell. 2020 Aug 20;182(4):812-827.e19
pubmed: 32697968
Virology. 2008 Mar 15;372(2):300-12
pubmed: 18054979
Cell Host Microbe. 2020 Sep 9;28(3):475-485.e5
pubmed: 32735849
Science. 2020 Sep 25;369(6511):1586-1592
pubmed: 32694201
Pathog Immun. 2020 Oct 19;5(1):342-363
pubmed: 33154981
Biotechnology (N Y). 1991 Dec;9(12):1356-61
pubmed: 1370252
Mol Immunol. 2006 Apr;43(11):1791-8
pubmed: 16423399
J Virol. 2008 Nov;82(22):11318-30
pubmed: 18753196
Curr Med Chem. 2008;15(10):997-1005
pubmed: 18393857
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
Proc Natl Acad Sci U S A. 2014 Nov 25;111(47):16866-71
pubmed: 25385608
Rev Med Virol. 2018 Jan;28(1):
pubmed: 29218769
Nat Commun. 2021 Jan 21;12(1):502
pubmed: 33479198
Proc Natl Acad Sci U S A. 2008 Apr 15;105(15):5839-43
pubmed: 18391206
Front Immunol. 2020 Jul 03;11:1581
pubmed: 32719684
Cell Host Microbe. 2020 Sep 9;28(3):486-496.e6
pubmed: 32738193
Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
Science. 1989 Mar 3;243(4895):1188-91
pubmed: 2922607
J Cell Biochem. 2013 Jun;114(6):1271-85
pubmed: 23192782
Biochem Biophys Res Commun. 2019 Dec 10;520(3):499-506
pubmed: 31594639
J Exp Med. 2020 Nov 2;217(11):
pubmed: 32692348
Trials. 2020 Oct 15;21(1):853
pubmed: 33059771
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Front Bioeng Biotechnol. 2020 Jul 30;8:862
pubmed: 32850726
Signal Transduct Target Ther. 2020 Nov 17;5(1):269
pubmed: 33203855
Nature. 2020 Oct;586(7830):567-571
pubmed: 32756549
N Engl J Med. 2020 Nov 12;383(20):1920-1931
pubmed: 32663912
Nat Microbiol. 2019 May;4(5):813-825
pubmed: 30833724
Cell. 1994 Nov 4;79(3):497-506
pubmed: 7954815
Proc Natl Acad Sci U S A. 2020 Apr 7;117(14):8055-8063
pubmed: 32193343
Acta Pharmacol Sin. 2020 Sep;41(9):1141-1149
pubmed: 32747721
Lancet. 2020 Mar 21;395(10228):949-950
pubmed: 32151324
Nat Rev Microbiol. 2021 Mar;19(3):155-170
pubmed: 33116300
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
Nature. 2003 Nov 27;426(6965):450-4
pubmed: 14647384
Sci Rep. 2020 Aug 20;10(1):14031
pubmed: 32820179
Protein J. 2020 Jun;39(3):198-216
pubmed: 32447571
J Virol. 2011 Jun;85(12):5764-72
pubmed: 21490100
Viruses. 2020 Dec 30;13(1):
pubmed: 33396594
iScience. 2019 Nov 22;21:391-402
pubmed: 31704650
J Gen Virol. 2004 Oct;85(Pt 10):3109-3113
pubmed: 15448374
Nat Microbiol. 2020 Apr;5(4):536-544
pubmed: 32123347
Emerg Microbes Infect. 2020 Dec;9(1):680-686
pubmed: 32207377
EBioMedicine. 2021 Mar;65:103255
pubmed: 33676899
Lancet. 2021 Dec 19;396(10267):1979-1993
pubmed: 33220855
J Virol Methods. 2010 Nov;169(2):365-74
pubmed: 20709108
Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):2679-83
pubmed: 1372987
Nat Rev Microbiol. 2015 Aug;13(8):484-96
pubmed: 26119571
J Virol. 2005 Nov;79(22):13848-55
pubmed: 16254320
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9537-9545
pubmed: 32273392
Methods Mol Med. 1998;13:237-55
pubmed: 21390848
Nat Protoc. 2020 Nov;15(11):3699-3715
pubmed: 32978602
Nature. 2020 Oct;586(7827):113-119
pubmed: 32707573
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508
Biosaf Health. 2020 Dec;2(4):226-231
pubmed: 32864605